Biotech Breakthrough: The $450K Treatment That Could Save 30,000 Lives | IMMX CEO & CFO Interview

In this exclusive Stocktwits executive interview, Katie Perry sits down with Dr. Ilya Rachman (CEO) and Gabriel Morris (CFO) of IMMX (Immix Biopharma) to uncover how they’re racing toward FDA approval for a revolutionary therapy targeting relapsed/refractory AL amyloidosis, a rare, deadly disease with no current approved treatments.

We discuss:

The urgent problem $IMMX is solving for 30,000 U.S. patients
How their $450,000 per dose treatment could transform lives—and the biotech market
The accelerated FDA approval path that could fast-track them to revenue by 2026
Why Wall Street and the medical community are both watching closely
The potential for big pharma buyout interest as they near their pivotal milestone

If you’re an investor, biotech enthusiast, or just curious about groundbreaking medical innovation, this is an interview you can’t afford to miss.

📌 Chapters:
00:00 – Intro: Katie Perry welcomes IMMX leadership
00:50 – The urgent mission to treat AL amyloidosis
01:57 – Breaking down the disease for non-medical audiences
03:04 – Why IMMX chose this challenge and technology
04:21 – Current trial stage and FDA accelerated approval path
05:28 – What qualifies IMMX for accelerated approval
06:43 – Balancing investor and medical community trust
07:20 – The role of scientific validation in biotech adoption
08:34 – Financial strategy and market opportunity
09:39 – Pushing toward FDA approval as quickly as possible
10:57 – Communicating the IMMX story to retail investors
11:48 – Key investor questions: Does it work? What’s the opportunity? When’s it coming?
13:11 – Potential for big pharma acquisition interest
13:28 – Closing thoughts and future updates

Join Our Community! https://stocktwits.com/
Sign up for our daily FREE newsletter to keep in touch with the market: https://thedailyrip.stocktwits.com/

Disclaimer:
All opinions expressed on this show are solely the opinions of the hosts’ and guests’ and do not reflect the opinions of Stocktwits, Inc. or its affiliates. The hosts are not SEC or FINRA registered advisors or professionals. The content of this show is for educational and entertainment purposes only. Please consult with your financial advisor before making any investment decision. Read the full terms & conditions here: https://stocktwits.com/about/legal/te...